Anakinra was approved by the Food and Drug Administration (FDA) in 2012 for chronic infantile neurological cutaneous and articular syndrome (CINCA) and in 2013 by the European Medicines Agency (EMA) for all subtypes of cryopyrin-associated periodic syndrome (CAPS). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.